Testing of the Akt/PKB Inhibitor MK-2206 by the Pediatric Preclinical Testing Program

BACKGROUND: MK-2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer. PROCEDURES: MK-2206 was tested against the PPTP in vitro panel using a 96 hour exposure (1.0 nM-10 μM), and in vivo using thrice weekly dosing for a planned 4 weeks at...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gorlick, Richard, Maris, John M., Houghton, Peter J., Lock, Richard, Carol, Hernan, Kurmasheva, Raushan T., Kolb, E. Anders, Keir, Stephen T., Reynolds, C. Patrick, Kang, Min H., Billups, Catherine A., Smith, Malcolm A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3290691/
https://ncbi.nlm.nih.gov/pubmed/22102563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.23412
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky